Simone Mathoulin-Pelissier
Overview
Explore the profile of Simone Mathoulin-Pelissier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
131
Citations
2144
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Belaroussi Y, Bouteiller F, Bellera C, Pasquier D, Perol M, Debieuvre D, et al.
Sci Rep
. 2023 Jun;
13(1):9584.
PMID: 37311845
Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in...
12.
Richez B, Cantarel C, Durrieu F, Soubeyran I, Blanchi J, Pernot S, et al.
Int J Environ Res Public Health
. 2023 Jun;
20(11).
PMID: 37297553
Infection of SARS-CoV-2 among health workers (HWs) in contact with cancer patients has been a major issue since the beginning of the pandemic. We aimed to assess the serological immune...
13.
Belaroussi Y, Hustache-Castaing R, Maury J, Lehot L, Rodriguez A, Demant X, et al.
Eur J Cardiothorac Surg
. 2023 Apr;
63(5).
PMID: 37099715
Objectives: A lung transplant is the final treatment option for end-stage lung disease. We evaluated the individual risk of 1-year mortality at each stage of the lung transplant process. Methods:...
14.
Courtinard C, Gourgou S, Jacot W, Carton M, Guerin O, Vacher L, et al.
BMC Med
. 2023 Mar;
21(1):87.
PMID: 36882736
Background: Overall survival (OS) is the gold standard endpoint to assess treatment efficacy in cancer clinical trials. In metastatic breast cancer (mBC), progression-free survival (PFS) is commonly used as an...
15.
Poiseuil M, Payet C, Molinie F, Dabakuyo-Yonli T, Mathoulin-Pelissier S, Amadeo B, et al.
Cancer Epidemiol
. 2022 Dec;
82:102312.
PMID: 36508966
Background: Many studies have investigated the survival of women by comparing those who participated in organised screening with those who did not. However, among those who do not participate in...
16.
Maire M, Debled M, Petit A, Fournier M, MacGrogan G, Quenel-Thueux N, et al.
Eur J Surg Oncol
. 2022 May;
48(8):1699-1705.
PMID: 35523623
Background: The reverse sequence of neoadjuvant chemotherapy, preoperative radiotherapy, mastectomy then immediate breast reconstruction is currently proposed for selected patients with locally advanced breast cancer. Few studies have compared it...
17.
Canoui-Poitrine F, Martinez-Tapia C, Paillaud E, Mathoulin-Pelissier S, Pamoukdjian F, Frasca M, et al.
J Clin Epidemiol
. 2022 Apr;
148:17-26.
PMID: 35398191
Objectives: We assessed the direct and indirect effects between six geriatric domains and 6- and 12-month mortality in older cancer patients. Study Design And Setting: We included cancer patients aged...
18.
Amadeo B, Penel N, Coindre J, Ray-Coquard I, Plouvier S, Delafosse P, et al.
Cancer
. 2022 Apr;
128(13):2483-2492.
PMID: 35385134
Background: Sarcomas are rare, heterogeneous, ubiquitously localized malignancies with many histologic subtypes and genomic patterns. The survival of patients with sarcoma has rarely been described based on this heterogeneity; therefore,...
19.
Greillier L, Gauvrit M, Paillaud E, Girard N, Montegut C, Boulahssass R, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35159036
Systematic molecular profiling and targeted therapy (TKI) have changed the face of Non-Small Cell Lung Cancer (NSCLC) treatment. However, there are no specific recommendations to address the prescription of TKI...
20.
Toulmonde M, Brahmi M, Giraud A, Chakiba C, Bessede A, Kind M, et al.
Clin Cancer Res
. 2021 Dec;
28(9):1765-1772.
PMID: 34965951
Purpose: Trabectedin has shown preclinical synergy with immune checkpoint inhibitors in preclinical models. Patients And Methods: TRAMUNE is a phase Ib study investigating the combination of trabectedin with durvalumab through...